Page 5 - அறிக்கை தொடர்பாக முன்னோக்கி பார்க்கிறது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced  mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and Translate Bio Board

France generalEva schaefer jansenArnaud delepineSuzanne grecoFelix lauscherMaura gavaghanFara berkowitzSanofi pasteurAshleigh kossPaul hudsonNathalie phamSandrine guendoulTeri dahlmanRonald renaudExchange commissionWharton garrison